Examples include rituximab directed against CD20 on malignant B cells, trastuzumab against Her-2/neu on, e.g., subsets of breast cancer cells, and cetuximab, recognizing epidermal growth factor receptor (EGFR) that is overexpressed on many epithelial cancers. This evidence concerns the gene EGFR and breast cancer.